This article is more than 5 years old. Information may no longer be current.

FDA pushes back action date for priority review of wet AMD treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TARRYTOWN, N.Y. - The U.S. Food and Drug Administration has extended its estimated completion date for the priority review of Regeneron's Eylea Biologics License Application by 3 months, according to a company press release.

The FDA implemented the extension in order to allow more time to review recent feedback regarding the chemistry, manufacturing and controls section of the license application. The new target date for completing the review of the license application is Nov. 18, according to the release.

Eylea, which is also known as VEGF Trap-Eye (aflibercept ophthalmic solution), is an intravitreal injection designed to treat neovascular age-related macular degeneration.